The New Pragmatism: Clinical Trials, Investment and Regulations Post-COVID-19

July 30, 2020

Once the COVID-19 pandemic passes or is contained, the world will look and work very differently. The biopharmaceutical industry is no exception. In this podcast, Peyton Howell, Parexel’s Chief Commercial and Strategy Officer, talks with Paul Bridges, Worldwide Head of Regulatory and Access, and Sheela Hegde, a Partner with Parexel’s Health Advances subsidiary, about the regulatory, investing and clinical development changes that are most likely here to stay – The New Pragmatism.

Previous Article
Against All Odds: Can Covid-19 Usher in a New Era in International Public Health Cooperation?
Against All Odds: Can Covid-19 Usher in a New Era in International Public Health Cooperation?

Key Takeaways The COVID-19 pandemic has drawn attention to international efforts to promote...

Next Article
Demystifying SARS-CoV-2 Testing for COVID-19 (Third Edition – Part 1: Updates and Trends)
Demystifying SARS-CoV-2 Testing for COVID-19 (Third Edition – Part 1: Updates and Trends)

Click here to download the full presentation. SummaryAs the world continues to battle...